By: Brittany Cote From: onclive.com William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research. Concurrent treatment with α-tocopheryloxyacetic acid (TEA) and trastuzumab (Herceptin) could possess the potential to induce clinical activity and augment type 1 (Th1) antitumor immunity in patients with HER2-positive metastatic breast cancer who have …
-
-
Psyching Ourselves Out in a Positive Way as a Breast Cancer Survivor
-
My Home is My Haven for This Breast Cancer Survivor
-
As a Breast Cancer Survivor, There is Nothing Like Doing What You Love
-
The True Meaning of Easter
-
Peace for a Breast Cancer Survivor
